A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer

NCT02012920 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Castration-resistant Prostate Cancer
CRPC

Interventions

DRUG: Seviteronel: given orally once daily in 28 day cycles

Sponsor

Innocrin Pharmaceutical